Your browser doesn't support javascript.
loading
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg, A J; Liao, C-Y; Karrison, T; de Souza, J A; Worden, F P; Libao, B; Krzyzanowska, M K; Hayes, D N; Winquist, E; Saloura, V; Prescott, K; Villaflor, V M; Seiwert, T Y; Schechter, R B; Stadler, W M; Cohen, E E W; Vokes, E E.
Affiliation
  • Rosenberg AJ; Department of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA. Electronic address: Arirosenberg@medicine.bsd.uchicago.edu.
  • Liao CY; Department of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA.
  • Karrison T; Department of Public Health Sciences, University of Chicago, Chicago, USA.
  • de Souza JA; HCA Healthcare, Nashville, USA.
  • Worden FP; University of Michigan Comprehensive Cancer Center, Ann Arbor, USA.
  • Libao B; Department of Medicine, University of Chicago, Chicago, USA.
  • Krzyzanowska MK; Princess Margaret Cancer Centre, Toronto, Canada.
  • Hayes DN; Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, USA.
  • Winquist E; Department of Oncology, University of Western Ontario and London Health Sciences Centre, London, Canada.
  • Saloura V; National Cancer Institute, Bethesda, USA.
  • Prescott K; University of Illinois Chicago, Chicago, USA.
  • Villaflor VM; City of Hope Comprehensive Cancer Center, Duarte, USA.
  • Seiwert TY; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA.
  • Schechter RB; Department of Medicine, University of Chicago, Chicago, USA.
  • Stadler WM; Department of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA.
  • Cohen EEW; Moores Cancer Center at UC San Diego, La Jolla, USA.
  • Vokes EE; Department of Medicine, University of Chicago, Chicago, USA; University of Chicago Comprehensive Cancer Center, Chicago, USA.
Ann Oncol ; 34(8): 714-722, 2023 08.
Article in En | MEDLINE | ID: mdl-37182801
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Adenocarcinoma Type of study: Clinical_trials Limits: Humans / Infant Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Adenocarcinoma Type of study: Clinical_trials Limits: Humans / Infant Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article